AR118171A1 - Preparaciones de membrana bacteriana - Google Patents
Preparaciones de membrana bacterianaInfo
- Publication number
- AR118171A1 AR118171A1 ARP200100496A ARP200100496A AR118171A1 AR 118171 A1 AR118171 A1 AR 118171A1 AR P200100496 A ARP200100496 A AR P200100496A AR P200100496 A ARP200100496 A AR P200100496A AR 118171 A1 AR118171 A1 AR 118171A1
- Authority
- AR
- Argentina
- Prior art keywords
- membrane preparations
- bacterial membrane
- bacterial
- preparations
- useful
- Prior art date
Links
- 239000012528 membrane Substances 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- 230000001580 bacterial effect Effects 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464401—Neoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/04—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/50—Colon
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
Se proporcionan en el presente documento métodos y composiciones relacionadas con preparaciones de membrana (MP) útiles como agentes terapéuticos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962809292P | 2019-02-22 | 2019-02-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR118171A1 true AR118171A1 (es) | 2021-09-22 |
Family
ID=70005742
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP200100496A AR118171A1 (es) | 2019-02-22 | 2020-02-21 | Preparaciones de membrana bacteriana |
Country Status (13)
Country | Link |
---|---|
US (1) | US20220118030A1 (es) |
EP (1) | EP3927356A2 (es) |
JP (1) | JP2022520999A (es) |
KR (1) | KR20210133986A (es) |
CN (1) | CN113727722A (es) |
AR (1) | AR118171A1 (es) |
AU (1) | AU2020225473A1 (es) |
BR (1) | BR112021016605A2 (es) |
CA (1) | CA3130776A1 (es) |
CO (1) | CO2021012176A2 (es) |
MX (1) | MX2021010160A (es) |
TW (1) | TW202045192A (es) |
WO (1) | WO2020172492A2 (es) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111518781B (zh) * | 2019-07-31 | 2022-02-15 | 江南大学 | 一种谷氨酰胺转氨酶复合酶及其在人造肉加工中的应用 |
AU2020358720A1 (en) | 2019-10-01 | 2022-04-21 | Empyrean Neuroscience, Inc. | Genetic engineering of fungi to modulate tryptamine expression |
US20240066074A1 (en) * | 2020-09-11 | 2024-02-29 | California Institute Of Technology | Probiotic treatments for parkinson's disease |
WO2022098961A1 (en) * | 2020-11-06 | 2022-05-12 | Evelo Biosciences, Inc. | Inducing immune effects using veillonella parvula bacteria |
EP4259806A1 (en) * | 2020-12-14 | 2023-10-18 | Evelo Biosciences, Inc. | Extracellular vesicle preparations |
EP4284400A1 (en) * | 2021-01-26 | 2023-12-06 | Evelo Biosciences, Inc. | Prevotella extracellular vesicle preparations |
CN112899188A (zh) * | 2021-01-29 | 2021-06-04 | 西南大学 | 一种促进作物根系发育的微生物菌剂及其制备与应用 |
WO2022187578A1 (en) * | 2021-03-05 | 2022-09-09 | Evelo Biosciences, Inc. | Solid dosage forms |
KR102582570B1 (ko) * | 2021-03-19 | 2023-09-22 | 한국생명공학연구원 | 유박테리움 칼란데리, 이의 배양액 또는 이의 배양액 추출물을 유효성분으로 포함하는 암 예방 또는 치료용 조성물 |
CN115305211A (zh) * | 2021-05-07 | 2022-11-08 | 葡萄王生技股份有限公司 | 益生菌胞外泌体及其用途 |
WO2023278557A1 (en) * | 2021-06-30 | 2023-01-05 | Kiverdi, Inc. | Reduction of endotoxins in bacterial protein preparations |
EP4376880A1 (en) * | 2021-07-28 | 2024-06-05 | The Texas A&M University System | Vaccine compositions comprising brucella strains and methods thereof |
WO2023068855A1 (ko) * | 2021-10-20 | 2023-04-27 | 주식회사 고바이오랩 | 항암 활성을 갖는 베일로넬라 파르불라 균주를 이용한 암의 완화, 예방 또는 치료용 조성물 |
CN114085875B (zh) * | 2021-11-10 | 2023-04-25 | 四川大学 | 一种胞外多糖、制备方法及其应用 |
CN114410503B (zh) * | 2021-12-08 | 2023-10-03 | 中南大学 | 一种锰氧化菌及其筛选方法和应用 |
WO2023114295A1 (en) * | 2021-12-14 | 2023-06-22 | Evelo Biosciences, Inc. | Veillonella parvula bacteria extracellular vesicle preparations |
TWI819483B (zh) * | 2022-01-28 | 2023-10-21 | 加捷生醫股份有限公司 | 乳酸菌組成物及其用於製備抑制抗藥性腸桿菌之口服組成物的用途 |
CN114262683B (zh) * | 2022-03-01 | 2022-06-17 | 中国科学院动物研究所 | 一种表达vegfr3 d2多肽的细菌制剂及其构建方法和应用 |
WO2023195008A1 (en) * | 2022-04-05 | 2023-10-12 | Mybiotics Pharma Ltd. | Bacterial compositions and methods for growing bacteria on particles |
WO2023215869A2 (en) * | 2022-05-06 | 2023-11-09 | Biological Mimetics, Inc. | Inactivated staphylococcus compositions and methods of making and using the same |
KR102551061B1 (ko) * | 2022-05-26 | 2023-07-03 | 중앙대학교 산학협력단 | Saha를 유효성분으로 포함하는 살모넬라 속 균주에 의한 바이오필름 생성 저해용 조성물 |
WO2023239728A1 (en) * | 2022-06-07 | 2023-12-14 | Evelo Biosciences, Inc. | Compositions and methods of treating inflammation using prevotella histicola extracellular vesicles |
KR102509869B1 (ko) * | 2022-07-14 | 2023-03-14 | 주식회사 엔테로바이옴 | 아커만시아를 포함하는 탈모 예방 또는 치료용 약학적 조성물 |
CN115607573B (zh) * | 2022-12-16 | 2023-05-23 | 北京大学第三医院(北京大学第三临床医学院) | 一种用于调节杀伤性t细胞活性的方法、药物及其应用 |
CN116236610A (zh) * | 2022-12-28 | 2023-06-09 | 四川大学 | 一种多酚修饰zif装载活性分子的丝素蛋白和明胶复合支架及其制备方法和用途 |
KR102555748B1 (ko) * | 2023-03-23 | 2023-07-17 | 주식회사 그린스토어 | 항균, 항진균, 항염 활성 및 치아 우식 억제 활성을 갖는 신규한 스트렙토코커스 살리바리우스 균주 kccm13161p 및 이를 포함하는 구강용 조성물 |
CN116212091B (zh) * | 2023-05-09 | 2023-08-01 | 天津包钢稀土研究院有限责任公司 | 一种复合抗菌剂、人体友好型医用抗菌敷料及其制备方法 |
CN116794313B (zh) * | 2023-08-18 | 2023-11-03 | 江西赛基生物技术有限公司 | 基于流式细胞仪同时检测三项肿瘤标志物的试剂盒及方法 |
CN117683654A (zh) * | 2023-10-11 | 2024-03-12 | 青岛大学附属医院 | 一种产尿酸氧化酶的菌株44xb及其应用 |
CN117264850B (zh) * | 2023-11-09 | 2024-05-14 | 潍坊君薇生物科技有限责任公司 | 一种具有辅助治疗阴道炎和增强免疫力功能的戊糖片球菌sw006及其应用 |
CN117264854B (zh) * | 2023-11-17 | 2024-01-26 | 云南农业大学 | 一种植物乳杆菌及其应用 |
CN117402794B (zh) * | 2023-12-12 | 2024-02-27 | 四川厌氧生物科技有限责任公司 | 一种加氏乳杆菌及其应用 |
CN117603884B (zh) * | 2024-01-17 | 2024-03-26 | 广州同康生物科技有限公司 | 一种嗜黏蛋白阿克曼氏菌菌粉及其制备方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2523154A1 (fr) * | 1982-03-09 | 1983-09-16 | Fabre Sa Pierre | Procede de preparation de proteoglycanes immunostimulants inducteurs d'interferon, proteoglycanes obtenus et medicaments les contenant |
DE19703437A1 (de) * | 1997-01-30 | 1998-08-06 | Luitpold Pharma Gmbh | Gemische äußerer Membranen und/oder Zellwände von Bakterien zur oralen Immunisierung gegen Schleimhautinfektionen |
FR2790960B1 (fr) * | 1999-03-15 | 2002-10-31 | Pf Medicament | Utilisation de fractions membranaires bacteriennes a activite immunostimulante dans le traitement de cancers, leurs procedes de preparation et les compositions pharmaceutiques les contenant |
FR2822071B1 (fr) * | 2001-03-15 | 2005-07-01 | Pf Medicament | Utilisation d'une fraction membranaire de bacteries a gram negatif pour induire la maturation des cellules dendritiques |
GB0220194D0 (en) * | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
GB0424092D0 (en) * | 2004-10-29 | 2004-12-01 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
CA2840096C (en) * | 2011-07-07 | 2021-07-06 | Bas VAN DE WATERBEEMD | A process for detergent-free production of outer membrane vesicles of a gram-negative bacterium |
MX363529B (es) * | 2012-09-18 | 2019-03-27 | Novartis Ag | Vesículas de membrana externa. |
KR20200053531A (ko) * | 2017-09-08 | 2020-05-18 | 에벨로 바이오사이언시즈, 인크. | 박테리아 세포외 소포 |
WO2020006216A1 (en) * | 2018-06-27 | 2020-01-02 | Evelo Biosciences, Inc. | Compositions and methods of treating cancer using neisseria bacteria |
-
2020
- 2020-02-21 TW TW109105678A patent/TW202045192A/zh unknown
- 2020-02-21 JP JP2021549229A patent/JP2022520999A/ja active Pending
- 2020-02-21 KR KR1020217030263A patent/KR20210133986A/ko unknown
- 2020-02-21 AR ARP200100496A patent/AR118171A1/es unknown
- 2020-02-21 EP EP20714360.3A patent/EP3927356A2/en active Pending
- 2020-02-21 BR BR112021016605A patent/BR112021016605A2/pt not_active IP Right Cessation
- 2020-02-21 CN CN202080016014.6A patent/CN113727722A/zh active Pending
- 2020-02-21 US US17/432,846 patent/US20220118030A1/en active Pending
- 2020-02-21 AU AU2020225473A patent/AU2020225473A1/en not_active Abandoned
- 2020-02-21 MX MX2021010160A patent/MX2021010160A/es unknown
- 2020-02-21 CA CA3130776A patent/CA3130776A1/en active Pending
- 2020-02-21 WO PCT/US2020/019154 patent/WO2020172492A2/en unknown
-
2021
- 2021-09-16 CO CONC2021/0012176A patent/CO2021012176A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2020172492A2 (en) | 2020-08-27 |
US20220118030A1 (en) | 2022-04-21 |
KR20210133986A (ko) | 2021-11-08 |
MX2021010160A (es) | 2021-09-14 |
TW202045192A (zh) | 2020-12-16 |
BR112021016605A2 (pt) | 2022-01-18 |
CA3130776A1 (en) | 2020-08-27 |
AU2020225473A1 (en) | 2021-09-30 |
EP3927356A2 (en) | 2021-12-29 |
CO2021012176A2 (es) | 2021-09-30 |
WO2020172492A3 (en) | 2020-10-08 |
JP2022520999A (ja) | 2022-04-04 |
CN113727722A (zh) | 2021-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2021012176A2 (es) | Preparaciones de membrana bacteriana | |
CO2020004233A2 (es) | Vesículas extracelulares bacterianas | |
CO2022000040A2 (es) | Vesículas extracelulares microbianas procesadas | |
MX2020002660A (es) | Vesiculas extracelulares de prevotella. | |
ECSP20004580A (es) | Moduladores de moléculas pequeñas de sting humana | |
MX2020009347A (es) | Picolinamidas como fungicidas. | |
BR112019005595A2 (pt) | compostos e métodos para modulação de ido e tdo, e indicações para os mesmos | |
CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
CL2019002135A1 (es) | Células microbianas, métodos para producir las mismas, y usos de las mismas. | |
AR120534A1 (es) | Aislados paenibacillus y sus usos | |
CL2020001442A1 (es) | Conjugados anticuerpo anti-cd40-fármaco. | |
CO2019009612A2 (es) | Proteinas de unión a antígeno anti-tigit y métodos de uso de las mismas | |
CY1124761T1 (el) | Ρυθμιστες της δραστικοτητας του συμπληρωματος | |
WO2019178487A3 (en) | Compositions and methods for treating disease using klebsiella quasipneumoniae subsp. similipneumoniae | |
BR112019000693A2 (pt) | composições de muc1- car e métodos para uso | |
CO2020016678A2 (es) | Tiofenocarboxamidas sustituidas y análogos como agentes antibacterianos | |
CO2022002066A2 (es) | Métodos y composiciones para cultivar bacterias dependientes de hemoglobina | |
ECSP20082988A (es) | Agonistas de tlr7 | |
MX2020013389A (es) | Composiciones de terlipresina y usos de las mismas. | |
AR115359A1 (es) | Preparaciones microbianas para plantas, composiciones y formulaciones que las comprenden y sus usos | |
CL2021002108A1 (es) | Desinfectante endoscopico mejorado | |
CO2023000114A2 (es) | Composiciones y métodos para el tratamiento de enfermedades y trastornos usando vesículas extracelulares microbianas de oscillospiraceae | |
CO2021016916A2 (es) | Métodos y composiciones para la fermentación bacteriana anaerobia | |
CL2018002368A1 (es) | Formulaciones de oritavancina | |
AR120058A1 (es) | Vesículas extracelulares microbianas procesadas |